Today: The BioDelivery Sciences International, Inc. (BDSI) Receives Consensus Recommendation of “Hold” from Analysts

The BioDelivery Sciences International, Inc. (BDSI) Receives Consensus Recommendation of “Hold” from Analysts

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have been assigned an average rating of “Hold” from the seven research firms that are presently covering the firm. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.33.

Several research firms have recently weighed in on BDSI. Cantor Fitzgerald reissued a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday, July 9th. Janney Montgomery Scott restated a “hold” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a research note on Tuesday, July 12th. Piper Jaffray Cos. restated a “sell” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a research note on Wednesday, August 10th. Zacks Investment Research upgraded BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Thursday, July 14th. Finally, FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a research note on Tuesday, September 20th.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded up 3.4737% on Thursday, reaching $2.3592. 503,837 shares of the company’s stock traded hands. The company’s market cap is $126.55 million. The stock has a 50-day moving average price of $2.51 and a 200-day moving average price of $2.65. BioDelivery Sciences International has a 12-month low of $1.86 and a 12-month high of $7.04.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.31). The business earned $5 million during the quarter, compared to the consensus estimate of $3.35 million. BioDelivery Sciences International had a negative return on equity of 233.80% and a negative net margin of 109.64%. The company’s revenue was up 194.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.37) earnings per share. Equities research analysts anticipate that BioDelivery Sciences International will post ($1.14) EPS for the current fiscal year.

In other BioDelivery Sciences International news, insider Niraj Vasisht sold 47,000 shares of the company’s stock in a transaction on Friday, September 23rd. The stock was sold at an average price of $2.43, for a total value of $114,210.00. Following the sale, the insider now owns 73,081 shares of the company’s stock, valued at $177,586.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William B. Stone sold 16,000 shares of the company’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $2.57, for a total value of $41,120.00. Following the completion of the sale, the director now directly owns 122,675 shares in the company, valued at approximately $315,274.75. The disclosure for this sale can be found here. 9.00% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of BDSI. Emerald Acquisition Ltd. purchased a new stake in BioDelivery Sciences International during the second quarter valued at $2,711,000. Ameriprise Financial Inc. purchased a new stake in BioDelivery Sciences International during the second quarter valued at $2,104,000. Bank of Montreal Can purchased a new stake in BioDelivery Sciences International during the second quarter valued at $1,648,000. Royce & Associates LP raised its stake in BioDelivery Sciences International by 23.5% in the first quarter. Royce & Associates LP now owns 1,837,800 shares of the specialty pharmaceutical company’s stock valued at $5,936,000 after buying an additional 350,000 shares during the period. Finally, Oxford Asset Management purchased a new stake in BioDelivery Sciences International during the second quarter valued at $536,000. 60.12% of the stock is currently owned by institutional investors.

Related posts

Leave a Comment